A phase I clinical trial of CTX130, an allogeneic CD70-targeted CAR T-cell therapy, showed promising results in treating advanced clear cell renal cell carcinoma (ccRCC). The therapy demonstrated favorable preclinical proliferation and cytotoxicity profiles, with complete regression of RCC xenograft tumors. In the trial, 16 patients with relapsed/refractory ccRCC received CTX130, with 81.3% achieving disease control, including one patient with a durable complete response at 3 years. A next-generation CAR T construct, CTX131, showed improved expansion and efficacy in preclinical studies. The study highlights the potential of CD70-targeted allogeneic CAR T cells for treating ccRCC and other CD70+ malignancies. The trial also demonstrated an acceptable safety profile with no dose-limiting toxicities. CTX131, which includes edits to enhance CAR T-cell persistence and reduce immunosuppressive effects, showed improved antitumor activity in preclinical models. The study underscores the potential of CAR T-cell therapy in solid tumors, despite limited success in previous trials. The findings suggest that CD70-targeted allogeneic CAR T cells could offer a new treatment option for patients with ccRCC and other CD70+ malignancies.A phase I clinical trial of CTX130, an allogeneic CD70-targeted CAR T-cell therapy, showed promising results in treating advanced clear cell renal cell carcinoma (ccRCC). The therapy demonstrated favorable preclinical proliferation and cytotoxicity profiles, with complete regression of RCC xenograft tumors. In the trial, 16 patients with relapsed/refractory ccRCC received CTX130, with 81.3% achieving disease control, including one patient with a durable complete response at 3 years. A next-generation CAR T construct, CTX131, showed improved expansion and efficacy in preclinical studies. The study highlights the potential of CD70-targeted allogeneic CAR T cells for treating ccRCC and other CD70+ malignancies. The trial also demonstrated an acceptable safety profile with no dose-limiting toxicities. CTX131, which includes edits to enhance CAR T-cell persistence and reduce immunosuppressive effects, showed improved antitumor activity in preclinical models. The study underscores the potential of CAR T-cell therapy in solid tumors, despite limited success in previous trials. The findings suggest that CD70-targeted allogeneic CAR T cells could offer a new treatment option for patients with ccRCC and other CD70+ malignancies.